Supply Chain Intelligence about:
India
Generic drug manufacturer Aurobindo reported a 2.5% dip in FQ4’21 (to March 31) revenues as a result of lower formulated drug sales in the U.S. That is partly “due to a reduction in hospital procedures on the back of COVID-19” though requests for sales rep visits to doctor surgeries in the U.S... Read more →
The pharmaceutical industry represents India’s third largest export sector, accounting for 6% of exports in the past year. It’s been in decline, with shipments sliding 1% in dollar terms in the past year. The sector has also lagged the recent recovery in national exports. Volumes shipped have ... Read more →
The latest industry to face President-elect Trump’s attention is pharmaceutical manufacturing, where a commitment has been made to cut costs. While it is not clear how this will be achieved, the U.S. has made significant use of imported generic drugs once branded versions’ patents end. Panjiva... Read more →
U.S. imports of anticonvulsant drugs (AC), used for epilepsy, migraine and bipolar treatments, climbed 42% in October, the 18th straight increase. This was led by lamotrigine which jumped 150%. Generic drugmakers including Aurobindo Pharma, Cipla and Cadila have taken the lion’s share of the g... Read more →
中文